Oncology Industry Taskforce
On this page
About the Medicines Australia Oncology Industry Taskforce
Recently, cancer patients, medical professionals caring for cancer patients, and the medicines industry have expressed concerns about the increasing challenges in gaining timely, affordable and equitable patient access to new cancer medicines via the PBS (e.g. Kefford 2012; Tillett 2013; Prostate Cancer Foundation of Australia 2013).
The Oncology Industry Taskforce is aware that stakeholders have voiced various concerns, including differences in value perception of cancer medicines among stakeholders, stringent evidentiary requirements for reimbursement, and delays due to Federal Government fiscal measures. There is a clear demand for an informed public debate about accessing new medicines generally, and new cancer medicines in particular.
In response, several member companies of Medicines Australia formed the Oncology Industry Taskforce in late 2012. The companies involved are: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi Aventis and Takeda. This Taskforce is endorsed by Medicines Australia. Specifically, these companies decided to form the Taskforce against the background of an increasingly difficult reimbursement environment in Australia in relation to cancer medicines:
- 82% of cancer medicines seeking reimbursement on cost-effectiveness grounds were rejected in 2011;
- Up to 50 submissions relating to cancer medicines to the Pharmaceutical Benefits Advisory Committee (PBAC) are expected between now and the end of 2015; and
- There are increasing signs that the Government is looking to further contain spending for medicines.
The Taskforce is keen to work in collaboration with key stakeholders including government, health care professionals and societies, Cancer Australia, and consumer health organisations to improve access to cancer medicines for the benefit of patients.
To begin the dialogue, a few years ago it commissioned Deloittes Access Economics to produce Access to Cancer Medicines in Australia. See below
Reports by Michael Wonder – 2016
The Oncology Industry Taskforce commissioned Wonder Drug Consulting Pty Ltd (WDC) to prepare a report on access to new cancer medicines in Australia. WDC conducted an analysis on this issue in 2014. Timely access to new cancer medicines via the Pharmaceutical Benefits Scheme (PBS) remains an important public health care goal. The objective of the project was to update the 2014 analysis of submissions for new medicines for patients with cancer to the Pharmaceutical Benefits Advisory Committee (PBAC) and other comparable health technology assessment (HTA) agencies.
- Analysis of PBAC submissions and outcomes for medicines for patients with cancer (2010-2016) 810k
- Analysis of submissions and outcomes for medicines for patients with cancer; an international comparison (2010-2016) 925k
The 2016 reports follows on from Michael Wonder’s report, commisioned in late 2013 by the Oncology Industry Taskforce. This 2013 report comparing Australia’s access to cancer medicines to other countries entitled Reimbursement success rates and timelines for new medicines for cancer; an international comparison can be accessed here 554k
Access to Cancer Medicines 2013
This report was the first comprehensive assessment of stakeholder perspectives into access to new cancer medicines and highlights many challenges within the current system. It includes contribution from various cancer care stakeholders including health consumer organisations, clinicians, researchers, government and payers.
The report was launched at a sponsored symposium at the Medical Oncology Group of Australia’s (MOGA) Annual Scientific Meeting on 31 July 2013. The report can be accessed here 3,816k
Following the launch of the Access to Cancer Medicines in Australia report on Wednesday 31 July 2013, Medicines Australia through its Oncology Industry Taskforce invited submissions for comments/feedback on the initial findings of the Report.
One of the principal outcomes of the Report is the involvement of the wider community to participate in an informed and collaborative debate to identify how existing processes must progress to meet emerging challenges.
It is Medicine Australia’s preference that all submissions will be made publicly available on the Medicines Australia website; however Medicines Australia will keep a submission in confidence if requested.
Should you require any additional information please send an email to the Oncology Industry Taskforce
- Amgen 209k
- Anonymous letter 104k
- AstraZeneca 357k
- Bayer Australia 336k
- Bowel Cancer Australia 299k
- Brain Tumour Alliance Australia 215k
- Breast Cancer Network Australia 291k
- Bristol-Myers Squibb 61k
- Cancer Drugs Alliance 1,572k
- Cancer Voices Australia 459k
- CanSpeak 146k
- Cooperative Trials Group for Neuro Oncology (COGNO) 30k
- Consumers Health Forum of Australia 2,676k
- Fresenius Kabi Australia Pty Limited 1,319k
- Lung Foundation 789k
- Medical Oncology Group Australia (MOGA) 204k
- Melanoma Patients Australia 522k
- MSD 219k
- Novartis 319k
- Pharmacy Guild of Australia 176k
- Rare Cancers Australia 38k
- Roche 1,152k
- Sandoz 314k
- Society of Hospital Pharmacists 90k
- Sanofi 909k
- Takeda Pharmaceuticals Australia 4,833k
- Unicorn Foundation 139k